Alpex Acquisition Corporation (ALPX)
NASDAQ: ALPX · Real-Time Price · USD
9.94
-0.01 (-0.05%)
Sep 8, 2026, 4:00 PM EDT - Market closed
Company Description
Alpex Acquisition Corporation focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
The company was incorporated in 2026 and is based in Wilmington, Delaware.
Alpex Acquisition Corporation
| Country | United States |
| Founded | 2026 |
| IPO Date | Jun 25, 2026 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Xiaolin Zheng |
Contact Details
Address: 300 Delaware Ave., Suite 210 #494 Wilmington, Delaware 19801 United States | |
| Phone | 302 251 6637 |
Stock Details
| Ticker Symbol | ALPX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 2125551 |
| CUSIP Number | G63325107 |
| ISIN Number | KYG633251072 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel R. Vlock M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Gerald B. Pier Ph.D. | Co-Founder, Chief Scientific Officer and Chair of Scientific Advisory Board |
| Thomas T. Thomas II, C.F.A., CFA | Chief Financial Officer |
| Dr. William W. Chin M.D. | Senior Strategic Advisor and Director |
| Dr. Christine de los Reyes M.B.A., Pharm.D., PharmD | Chief Business Officer and Chief Commercialization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Jul 2, 2026 | SCHEDULE 13G | Filing |
| Jul 2, 2026 | SCHEDULE 13D | Filing |
| Jul 2, 2026 | 8-K | Current Report |
| Jul 2, 2026 | SCHEDULE 13G | Filing |